Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.

Aygun B. et al, (2024), Lancet Haematol, 11, e425 - e435

Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.

Kiguli S. et al, (2024), EClinicalMedicine, 72

A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial)

Maitland K. et al, (2024), Wellcome Open Research, 9, 281 - 281

Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.

Power-Hays A. et al, (2024), Am J Hematol

SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)

Maitland K. et al, (2024)

Impact of COVID-19 on mortality in coastal Kenya: a longitudinal open cohort study.

Otiende M. et al, (2023), Nat Commun, 14

The Dantu blood group prevents parasite growth in vivo: Evidence from a controlled human malaria infection study.

Kariuki SN. et al, (2023), Elife, 12

Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial.

Taylor WR. et al, (2023), Lancet Infect Dis, 23, 471 - 483

Mortality in rural coastal Kenya measured using the Kilifi Health and Demographic Surveillance System: a 16-year descriptive analysis

Otiende M. et al, (2023), Wellcome Open Research, 6, 327 - 327

Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial

Olupot-Olupot P. et al, (2023)

Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial

Olupot-Olupot P. et al, (2023)

SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).

Maitland K. et al, (2023), Wellcome Open Res, 8

Hydroxyurea is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.

Olupot-Olupot P. et al, (2022), Blood

Substantial misdiagnosis of severe malaria in African children.

White NJ. et al, (2022), Lancet, 400

Sickle cell anaemia and severe Plasmodium falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT).

Uyoga S. et al, (2022), Lancet Child Adolesc Health, 6, 606 - 613

The significance of spleen size in children with sickle cell anemia.

Nardo-Marino A. et al, (2022), Am J Hematol

BIRC6 modifies risk of invasive bacterial infection in Kenyan children.

Gilchrist JJ. et al, (2022), Elife, 11

Case Report: β-thalassemia major on the East African coast.

Macharia AW. et al, (2022), Wellcome Open Res, 7

The Childhood Acute Illness and Nutrition (CHAIN) network nested case-cohort study protocol: a multi-omics approach to understanding mortality among children in sub-Saharan Africa and South Asia.

Njunge JM. et al, (2022), Gates Open Res, 6

Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial.

Olupot-Olupot P. et al, (2021), Wellcome open research, 6

Load More

Include forthcoming?